Sanofi and Re­gen­eron out­line Dupix­ent plans; In­dus­try lob­by­ing brings £30 mil­lion for UK's Bio­med­ical Cat­a­lyst

→ Sanofi and Re­gen­eron out­lined the fu­ture for their block­buster IL-4/IL-13 block­er Dupix­ent in an in­vestor call and press re­lease yes­ter­day, high­light­ing five new in­di­ca­tions they hope to gain ap­proval in: Chron­ic ob­struc­tive pul­monary dis­ease, Eosinophilic esophagi­tis, Pruri­go nodu­laris, Chron­ic spon­ta­neous ur­ticaria, and Bul­lous pem­phigoid. The drug is in late-stage clin­i­cal tri­als for all five dis­eases, with the first po­ten­tial FDA sub­mis­sion com­ing in late 2021 for pruri­go nodu­laris.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER